AU Patent

AU2021245150C1 — KRAS G12C inhibitors and methods of using the same

Assigned to Amgen Inc · Expires 2025-11-06 · 1y expired

What this patent protects

KRAS G12C INHIBITORS AND METHODS OF USING THE SAME Provided herein are KRAS G 1 2C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers. KRAS G12C INH…

USPTO Abstract

KRAS G12C INHIBITORS AND METHODS OF USING THE SAME Provided herein are KRAS G 1 2C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers. KRAS G12C INHIBITORS AND METHODS OF USING THE SAME

Drugs covered by this patent

Patent Metadata

Patent number
AU2021245150C1
Jurisdiction
AU
Classification
—
Expires
2025-11-06
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.